The almighty oracle has spoken! [RSABE / ABEL]

posted by Helmut Homepage – Vienna, Austria, 2015-07-24 01:54 (3612 d 08:23 ago) – Posting: # 15139
Views: 31,765

Dear Dan et alii,

today the EMA published Rev. 12 of the Q&A-document (dated 25 June). See #23

Suitability of a 3-period replicate design scheme for the
demonstration of within-subject variability for Cmax

Essentially it says that CVwR is a “key parameter” and according to the GL a minimum of 12 subjects is needed for a “valid” BE study. In other words – and contrary to what the “leading European regulatory authority” told you – TRT|RTR is indeed acceptable if (‼) at least 12 subjects complete the RTR sequence.

Given the commonly applied T/R-ratio of 0.90 for HVD(P)s and ≥80% power this issue is practically not rele­vant. Full throttle for any study – unless you expect a lot (≥42%) of dropouts!

CVwR   N  nRTR  do.ratemax (%)
 25   42   21      42.9
 30   50   25      52.0
 40   40   20      47.8
 50   42   21      42.9
 60   48   24      50.0
 70   60   30      60.0
 80   74   37      67.6


[image]

[image]

Parturient montes, nascetur ridiculus mus. Horace (Ars poetica, Ep.II.3, 139)

Dif-tor heh smusma 🖖🏼 Довге життя Україна! [image]
Helmut Schütz
[image]

The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes

Complete thread:

UA Flag
Activity
 Admin contact
23,424 posts in 4,927 threads, 1,674 registered users;
13 visitors (0 registered, 13 guests [including 10 identified bots]).
Forum time: 10:17 CEST (Europe/Vienna)

A central lesson of science is that to understand complex issues
(or even simple ones), we must try to free our minds of dogma and
to guarantee the freedom to publish, to contradict, and to experiment.
Arguments from authority are unacceptable.    Carl Sagan

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5